elebsiran

Vir Completes Phase 3 Enrollment for Hepatitis Delta Trial

San Francisco, California – November 3, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on harnessing...

By cGxPwire Editor
November 3, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

elebsiran

Vir Completes Phase 3 Enrollment for Hepatitis Delta Trial